Mayo clinic tests popular Weight-Loss drugs on stomach function

NCT ID NCT06801015

Ongoing Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study at Mayo Clinic compares two FDA-approved weight-loss drugs, semaglutide and tirzepatide, against a placebo to see how they affect stomach emptying and feelings of fullness. Thirty adults with obesity or overweight plus prediabetes will receive weekly injections for 24 weeks. Researchers will measure stomach function using special imaging and calorie intake tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide and tirzepatide (weekly injections)
What this could lead to: If successful, this could help doctors understand how these weight-loss drugs work on the stomach, potentially improving treatment for obesity.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The drugs are already approved, but this trial focuses on stomach function, not weight loss directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.